Exhibit 107.1
Calculation of Filing Fee Tables
FORM S-3
Registration Statement under the Securities Act of 1933
(Form Type)
Relmada Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount | Proposed Maximum Offering Price per Unit (3) | Maximum Aggregate Offering Price | Fee Rate | Amount
of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing
Fee Previously Paid in Connection with Unsold Securities to Be Carried Forward | ||||||||||||||||||||||||||||||||
| Newly Registered Securities | |||||||||||||||||||||||||||||||||||||||||||
| Fees to be Paid | Equity(1) | Common Stock, $0.001 par value per share | Rule 457(o) | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Equity(1) | Preferred Stock, $0.001 par value per share | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Equity(1) | Depositary Shares | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Other(1) | Subscription Rights | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Other(1) | Warrants (4) | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Other(1) | Purchase Contracts | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Other(1) | Units | (2) | (3) | (3) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Unallocated (Universal) Shelf (1) | - | (2) | (3) | $ | 250,000,000 | (5) | $147.60 per $1,000,000 | $ | 36,900 | (5) | |||||||||||||||||||||||||||||||||
| Fees Previously Paid | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||
| Carry Forward Securities | |||||||||||||||||||||||||||||||||||||||||||
| Carry Forward Securities | Equity | Common Stock, $0.001 par value per share | Rule 415(a)(6) | (1)(6) | (3) | (3) | - | - | |||||||||||||||||||||||||||||||||||
| Equity | Preferred Stock, $0.001 par value per share | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Equity | Depositary Shares | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Subscription Rights | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Warrants (4) | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Purchase Contracts | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Units | Rule 415(a)(6) | (1)(6) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| $ | 77,500,000 | S-3 | 333-245054 | August 12, 2020 | $ | 7,184 | |||||||||||||||||||||||||||||||||||||
| Equity | Common Stock, $0.001 par value per share | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Equity | Preferred Stock, $0.001 par value per share | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Equity | Depositary Shares | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Subscription Rights | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Warrants (4) | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Purchase Contracts | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| Other | Units | Rule 415(a)(6) | (1)(7) | (3) | (3) | ||||||||||||||||||||||||||||||||||||||
| $ | 9,999,980 | S-3 | 333-234262 | October 18, 2019 | $ | 927 | |||||||||||||||||||||||||||||||||||||
| $ | 8,111 | ||||||||||||||||||||||||||||||||||||||||||
| Total Offering Amounts | $ | 250,000,000 | $ | 36,900 | |||||||||||||||||||||||||||||||||||||||
| Total Fees Previously Paid | $ | 8,111 | |||||||||||||||||||||||||||||||||||||||||
| Total Fee Offsets | - | ||||||||||||||||||||||||||||||||||||||||||
| Net Fee Due | $ | 28,789 | |||||||||||||||||||||||||||||||||||||||||
| (1) | Represents securities that may be offered and sold from time to time in one or more offerings by Relmada Therapeutics, Inc. (the “Registrant”) |
| (2) | An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. In no event will the aggregate offering price of all types of securities issued by the Registrant pursuant to this registration statement exceed $250,000,000. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction. |
| (3) | The proposed maximum aggregate offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act. |
| (4) | The warrants covered by this registration statement may be warrants for common stock, preferred stock, depositary shares or securities of third parties or other securities or rights. |
| (5) | Estimated solely to calculate the registration fee in accordance with Rule 457(o) under the Securities Act. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $250,000,000. |
| (6) | Pursuant to Rule 415(a)(6) under the Securities Act, this registration statement includes $77,500,000 of unsold securities (the “Unsold Securities”) that had previously been registered under the Registrant’s registration statement on Form S-3 (File No. 333-245054) initially filed on August 12, 2020, and effective on August 21, 2020 (the “Prior Registration Statement”) and paid a filing fee of $32,450 for an aggregate of $250,000,000 of securities that could have been issued under the Prior Registration Statement. Pursuant to Rule 415(a)(6), the Registrant is carrying forward to this registration statement the Unsold Securities that were previously registered on the Prior Registration Statement, and the aggregate filing fees of approximately $7,184 previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities that are being carried forward to this registration statement. |
| (7) | Pursuant to Rule 415(a)(6) under the Securities Act, this registration statement includes $9,999,980 of unsold securities (the “Unsold Securities”) that had previously been registered under the Registrant’s registration statement on Form S-3 (File No. 333-234262) initially filed on October 18, 2019, and effective on October 31, 2019 (“Prior Registration Statement”) and paid a filing fee of $25,960 for an aggregate of $200,000,000 of securities that could have been issued under the Prior Registration Statement. Pursuant to Rule 415(a)(6), the Registrant is carrying forward to this registration statement the Unsold Securities that were previously registered on the Prior Registration Statements, and the aggregate filing fees of approximately $927 previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities that are being carried forward to this registration statement. A filing fee of $9,270 with respect to the remaining $100,000,000 of securities registered hereunder is being paid herewith. Pursuant to Rule 415(a)(6), the offering of the Unsold Securities registered under the Prior Registration Statements will be deemed terminated as of the date of effectiveness of this registration statement. |